An absorbent product includes a liquid permeable topsheet, a liquid impermeable backsheet, and an absorbent core enclosed between the topsheet and the backsheet. The absorbent core includes an absorbent fibrous layer, a liquid inlet layer, and a carrier layer, in which a transversally central region is arranged in the liquid inlet layer. The central region extends along the entire longitudinal length of the absorbent core, and includes a plurality of slits arranged in a pattern. The slits are in the form of dilated slit openings in a part of said central region, which is comprised in an intermediate portion of the absorbent core, and the slits are in the form of non-dilated slits in parts of said central region, which are comprised in one or both of front and rear portions of the absorbent core.

The present invention relates to a resorbable implant material made of magnesium or magnesium alloy and to a process for the production thereof. A disadvantage of the known resorbable implants is that their resorption has hitherto only been trackable using x-ray or CT examinations. The invention provides a resorbable implant material comprising homogeneously distributed fluorescent nanodiamonds in a matrix of magnesium or a magnesium alloy. Fluorescent nanodiamonds are biologically nonhazardous and provide a stable emission in the near infrared range due to nitrogen-vacancy centers (NV centres). This allows detection of the implant material in the blood plasma of the patient.

The resorbable implant material according to the invention is produced by a process wherein magnesium or a magnesium alloy is melted, nanodiamonds are added to the melt and the melt of magnesium or a magnesium alloy provided with nanodiamonds is subjected to an ultrasound treatment.

Methods and compositions are for preparing microimplant arrays for sustained drug delivery or live cell based therapy. The array in array (AIA) device enables formation of microimplant arrays without having tissue piercing elements to the microimplant. The methods and compositions are for solid state delivery of drugs, especially biologics drugs without forming a drug solution prior to injection. New methods and compositions are for preparing in situ arrays for sustained drug delivery or live cell based therapy. Tissue surface is first treated with laser drilling, microneedle array, mechanical drilling or other methods to create artificial micro-porosity of various sizes, shapes and patterns. The artificial pores created are then infused with sustained drug delivery compositions or live cell suspensions. The compositions are converted into solid or semisolid state by physical or chemical reaction/s to entrap drug or live cells. The entrapped drug or live cells provide local or systemic therapeutic benefit.

Disclosed are methods for coating or impregnating a surface with an antimicrobial agent that involve contacting the surface with a composition that includes an antimicrobial agent and a solvent, and curing the surface by applying heat. Also disclosed are methods for reducing the risk of development or progression of an infection in a subject in need of a medical device, that involve coating or impregnating a surface of the medical device with an antimicrobial agent and then curing the surface by applying heat, wherein the risk of development or progression of an infection is reduced.

In one aspect, build materials for use with a three-dimensional (3D) printing system are described herein. In some embodiments, a build material described herein comprises an acrylate component, a photoinitiator component, a non-curable absorber component, and water. The photoinitiator component of the build material is operable to initiate curing of the acrylate component and/or other curable materials that may optionally be present when the photoinitiator is exposed to incident curing radiation having a Gaussian distribution of wavelengths and a peak wavelength . The build material has a penetration depth (D.sub.p) and a critical energy (E.sub.c) at the wavelength . In some embodiments, the D.sub.p is greater than 200 m and less than 300 m, and the E.sub.c is 3-12 mJ/cm.sup.2. In other embodiments, the D.sub.p is greater than 10 m and less than 50 m, and the E.sub.c is 5-40 mJ/cm.sup.2.

Some embodiments provided herein relate to methods, systems and kits for providing consistent intracoronary administration of a biologic to subjects having diverse coronary anatomies. In some embodiments, the biologic is an adeno-associated virus serotype 1 (AAV1) vector encoding sarcoplasmic/endoplasmic reticulum ATPase 2a (SERCA2a) protein.

One aspect of the invention provides a method of preventing or reducing stenosis in a subject. The method includes implanting a passivated graft comprising vein into an artery. The implanting of the graft replaces and/or bypasses a diseased segment of the artery. The passivated graft including vein is prepared by exposing the exterior surface of the passivated graft comprising vein to a tissue structure stabilizing agent (TSSA) under conditions sufficient to promote cross-linking of proteins within the vein.

A self-sealing vascular graft, including a substrate with a sealant layer and several optional additional layers, is described. The substrate can be ePTFE and the material used for the sealant and additional layers can be polyurethane. The sealant layer and additional layers may include one or more base layers, one or more foam layers, beading of different sizes and shapes, and ePTFE tape. A flared cuff may be integral to one or both ends of the substrate or may be attached to one or both ends. Various methods of making a self-sealing vascular graft are also described, including methods of disposition, methods of forming, methods of bonding and methods of attaching.

The present invention relates to settable compositions for use in surgery. The invention also provides related compositions, including surgical kits and packages, as well as methods of making and using the settable compositions.

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human.